The Pharmacy and Poisons Board (PPB), Kenya’s national drug regulatory authority, has lifted the quarantine order for Mefnac Oral Suspension (Mefnac Acid 50 mg/5ml), which had been imposed on December 11th. The decision was made following extensive investigations and quality control assessments, ensuring that the product meets all applicable safety and efficacy standards.
According to the Chief Executive Officer of PPB, the assessment focused on testing levels of Diethylene Glycol (DEG) and Ethylene Glycol (EG), which can pose health risks if found in excessive amounts. The results confirmed that Mefnac Oral Suspension adheres to required safety standards and is fit for distribution and use.
The PPB emphasized its ongoing commitment to ensuring that all medicines available in the market meet rigorous safety and quality standards. The authority reassured the public that continuous monitoring and strict regulatory processes are in place to safeguard public health.
The regulatory body also encouraged members of the public to report any suspected cases of substandard medicines or adverse drug reactions. Reports can be submitted to the nearest healthcare facility or directly to PPB for prompt investigation and necessary action.
To facilitate easy reporting, the public can reach PPB through various communication channels, including an online portal at https://pv.pharmacyboardkenya.org/users/mpublic. Additionally, reports can be made via the USSD code *271# or through email at pv@ppb.go.ke or pms@ppb.go.ke. The board also provides a direct telephone contact number, 0795743049, for inquiries and reporting concerns.
The lifting of the quarantine order comes as a relief to healthcare providers and consumers who rely on Mefnac Oral Suspension. The decision underscores the board’s dedication to conducting thorough evaluations before approving any pharmaceutical products for public consumption.
With a firm regulatory framework in place, the PPB continues to uphold its mission of ensuring that medicines distributed within the country meet international safety and quality standards. The public is encouraged to remain vigilant and promptly report any issues related to pharmaceuticals to contribute to a safer healthcare environment.
This development highlights the importance of stringent quality assurance measures in protecting consumers from potentially harmful medical products. By maintaining close oversight and implementing rigorous testing protocols, the regulatory authority aims to ensure that only safe and effective medications are available in the market.
